Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ALBT
Upturn stock ratingUpturn stock rating

Avalon GloboCare Corp. (ALBT)

Upturn stock ratingUpturn stock rating
$2.78
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ALBT (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $0

1 Year Target Price $0

Analysts Price Target For last 52 week
$0Target price
Low$
Current$2.78
high$

Analysis of Past Performance

Type Stock
Historic Profit -73.42%
Avg. Invested days 55
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 5.93M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 0.02
52 Weeks Range 2.11 - 11.66
Updated Date 06/29/2025
52 Weeks Range 2.11 - 11.66
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -8.01

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -243.34%

Management Effectiveness

Return on Assets (TTM) -23.8%
Return on Equity (TTM) -833.99%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 25157592
Price to Sales(TTM) 7.34
Enterprise Value 25157592
Price to Sales(TTM) 7.34
Enterprise Value to Revenue 18.38
Enterprise Value to EBITDA -4.45
Shares Outstanding 2132240
Shares Floating 1451691
Shares Outstanding 2132240
Shares Floating 1451691
Percent Insiders 23.35
Percent Institutions 0.83

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Avalon GloboCare Corp.

stock logo

Company Overview

overview logo History and Background

Avalon GloboCare Corp. (ALBT) is a biopharmaceutical company founded to develop and commercialize innovative exosome technologies and cellular therapeutics. The company aims to address unmet medical needs in cancer, infectious diseases, and autoimmune disorders. It was founded in 2017.

business area logo Core Business Areas

  • Exosome Technology: Develops and utilizes its Avalon Stem-Cell derived Exosomes (ASTEX) platform for therapeutic applications, including drug delivery and regenerative medicine.
  • Cellular Immunotherapy: Focuses on developing cellular immunotherapies, including CAR-T cell therapies, to target and eliminate cancer cells.
  • Drug Delivery: Developing technologies to deliver therapeutics directly to target cells, enhancing efficacy and reducing side effects.

leadership logo Leadership and Structure

David Jin is the President and CEO. The company operates with a scientific advisory board and a management team focused on research and development, clinical trials, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • ASTEX Platform: Avalon Stem-Cell derived Exosomes (ASTEX) is the company's core technology platform. Market share data is not readily available for this specific platform. Competitors in exosome therapeutics include companies like Codiak BioSciences (CDAK, now defunct) and Evox Therapeutics.
  • CAR-T Cell Therapy Programs: Avalon is developing CAR-T cell therapies for various cancers. Market share information is not publicly disclosed for Avalon's specific CAR-T programs. Major competitors in the CAR-T cell therapy field include Novartis (Kymriah), Gilead Sciences (Yescarta), and Bristol Myers Squibb (Breyanzi).

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and intense competition. The fields of exosome technology and cellular immunotherapy are rapidly growing with significant potential for treating a wide range of diseases.

Positioning

Avalon GloboCare Corp. positions itself as an innovator in exosome-based therapeutics and cellular immunotherapy, focusing on developing novel technologies and therapies for unmet medical needs. Competitive advantages include their proprietary ASTEX platform and their focus on specific cancer targets.

Total Addressable Market (TAM)

The global exosome market is expected to reach billions of dollars in the coming years, and the CAR-T cell therapy market is also projected to experience substantial growth. Avalon is positioned to capture a share of these markets with its innovative technologies.

Upturn SWOT Analysis

Strengths

  • Proprietary ASTEX platform technology
  • Focus on innovative exosome and cellular therapies
  • Experienced leadership team
  • Strategic partnerships

Weaknesses

  • Limited financial resources
  • Dependence on key personnel
  • Early stage of development
  • High risk of clinical trial failures

Opportunities

  • Growing demand for exosome and cellular therapies
  • Potential for strategic alliances and collaborations
  • Expansion into new therapeutic areas
  • Increasing awareness and acceptance of personalized medicine

Threats

  • Intense competition from established pharmaceutical companies
  • Regulatory hurdles and delays
  • Technological advancements by competitors
  • Market volatility and economic downturn

Competitors and Market Share

competitor logo Key Competitors

  • NVS
  • GILD
  • BMY
  • CRSP
  • EDIT

Competitive Landscape

Avalon faces significant competition from larger, more established pharmaceutical companies with greater resources. Its success depends on its ability to develop and commercialize innovative technologies.

Growth Trajectory and Initiatives

Historical Growth: Avalon's historical growth has been characterized by periods of rapid expansion followed by financial difficulties.

Future Projections: Future growth projections are highly uncertain and dependent on successful clinical trials, regulatory approvals, and securing additional funding.

Recent Initiatives: Recent initiatives include focusing on its exosome platform technology, restructuring operations, and seeking strategic partnerships.

Summary

Avalon GloboCare Corp. is a high-risk, high-reward biopharmaceutical company focusing on innovative exosome and cellular therapies. Its proprietary ASTEX platform and focus on personalized medicine provide potential advantages. Financial constraints, competition from larger players, and the inherent risks of clinical trials pose significant challenges. The company's success hinges on securing funding, achieving clinical milestones, and successfully commercializing its technologies.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Industry reports
  • Market research reports

Disclaimers:

This analysis is for informational purposes only and does not constitute investment advice. The data provided is based on available public information and may be subject to change. Invest at your own risk.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Avalon GloboCare Corp.

Exchange NASDAQ
Headquaters Freehold, NJ, United States
IPO Launch date 2016-12-06
CEO, President & Director Dr. David K. Jin M.D., Ph.D.
Sector Real Estate
Industry Real Estate Services
Full time employees 4
Full time employees 4

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States. It also distributes the KetoAir device, which is a breathalyzer system that detects acetone levels in exhaled breath; and the AI Nutritionist software program that helps users monitor and manage ketogenic diet and related programs. Avalon GloboCare Corp. was founded in 2015 and is headquartered in Freehold, New Jersey.